The Claim
In adults with type 2 diabetes, a low-carbohydrate diet (carbohydrate intake <20% of total energy) for 3 months results in a greater reduction in HbA1c (-2.23%) compared to canagliflozin (-1.76%), with an estimated difference of -0.47%.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, following a low-carbohydrate diet for three months lowers HbA1c by 2.23%, which is 0.47% more than the reduction seen with canagliflozin, a common diabetes medication.
See the scientific wording
In adults with type 2 diabetes, a low-carbohydrate diet (carbohydrate intake <20% of total energy) for 3 months leads to a greater reduction in HbA1c (-2.23%) compared to canagliflozin (-1.76%), with an estimated difference of -0.47%, suggesting that dietary carbohydrate restriction may be a more effective glycemic control strategy than this SGLT2 inhibitor in the short term.
When very little carbohydrate is eaten, the liver stops making extra sugar and starts using fat for energy. This lowers the amount of sugar in the blood. At the same time, muscle and fat cells become better at responding to insulin, so they take up more sugar from the blood. Together, these changes cause blood sugar levels to drop significantly.
What the research says
1 studyIn a study, people with type 2 diabetes who ate very few carbs lowered their blood sugar more than those who took the drug canagliflozin, and the difference was big enough to be meaningful.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.